Our Company

Board

Meet the people of the Capnia, Inc. Board of Directors who support our vision by providing additional expertise and insight to the development, implementation, and assessment of our company and its products.

Anish Bhatnagar, MDChief Executive Officer

Dr. Bhatnagar was appointed Chief Executive Officer in February 2014. He joined us in 2006, and has held positions of increasing responsibility since then, most recently as President and Chief Operating Officer. Dr. Bhatnagar is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic, as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000, and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts, and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India, and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.

Rajen Dalal

Mr. Dalal joined our board in April 2016. From 2011 until 2016, he served as the CEO of ReLIA Diagnostic Systems, Inc., a point-of-care diagnostics company selling blood tests used in emergency medicine, and served on ReLIA’s board from 2006 until its sale to Yunfeng Capital in 2015, and was managing director of Synergenics LLC, the company’s majority shareholder. From 2002 to 2005 Mr. Dalal served as CEO and a director of Guava Technologies, which commercialized a low cost bench top cytometer, which was FDA 510k cleared for AIDS/CD4 testing. From 1998 to 2002, he served as President of Chiron’s Blood Testing division, whose FDA cleared immunodiagnostic and DNA tests are used worldwide to screen blood donors for transfusion transmitted viruses. Mr. Dalal also served from 1992 to 1998 with Chiron as Vice President, Corporate Development. The Blood Testing Division was sold to Grifols for $1.7 billion. From 2003 to 2010, Mr. Dalal served on several boards including Ciphergen/Vermillion, a public ovarian cancer diagnostics company, has served on the board of Singapore based A-Bio Pharma and Dx Assays, and on the HHS Committee for Blood Safety and Availability. Prior to working in biotech, Mr. Dalal was at McKinsey & Co in New York and Cleveland. He is a graduate of the University of Chicago, MIT and St. Xavier’s College, Bombay with degrees in business, biochemical engineering and chemistry respectively. In 2007, he co-founded the San Francisco Bay Area Outward Bound, a youth-centered wilderness experience organization, and is an Emeritus Director.